State of New Jersey Common Pension Fund D lowered its position in shares of Laboratory Co. of America Holdings (NYSE:LH – Free Report) by 5.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 46,648 shares of the medical research company’s stock after selling 2,653 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Laboratory Co. of America were worth $9,379,000 as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of the company. Eagle Bay Advisors LLC acquired a new position in shares of Laboratory Co. of America during the second quarter valued at $29,000. Tradewinds Capital Management LLC acquired a new position in Laboratory Co. of America during the 3rd quarter valued at about $34,000. Exchange Traded Concepts LLC bought a new stake in shares of Laboratory Co. of America during the 3rd quarter worth about $37,000. ST Germain D J Co. Inc. acquired a new stake in shares of Laboratory Co. of America in the 2nd quarter worth approximately $43,000. Finally, Oakworth Capital Inc. boosted its holdings in shares of Laboratory Co. of America by 310.0% in the second quarter. Oakworth Capital Inc. now owns 246 shares of the medical research company’s stock valued at $59,000 after acquiring an additional 186 shares in the last quarter. Institutional investors and hedge funds own 89.37% of the company’s stock.
Insider Activity at Laboratory Co. of America
In other news, CAO Peter J. Wilkinson sold 1,384 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $210.71, for a total value of $291,622.64. Following the transaction, the chief accounting officer now directly owns 2,087 shares of the company’s stock, valued at $439,751.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CAO Peter J. Wilkinson sold 1,384 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $210.71, for a total transaction of $291,622.64. Following the transaction, the chief accounting officer now owns 2,087 shares in the company, valued at approximately $439,751.77. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 259 shares of Laboratory Co. of America stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $222.06, for a total transaction of $57,513.54. Following the completion of the sale, the executive vice president now directly owns 7,637 shares of the company’s stock, valued at approximately $1,695,872.22. The disclosure for this sale can be found here. 0.65% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Laboratory Co. of America Stock Down 0.1 %
NYSE:LH opened at $222.59 on Monday. The business’s fifty day moving average price is $223.49 and its 200 day moving average price is $213.20. The firm has a market capitalization of $18.90 billion, a price-to-earnings ratio of 29.76 and a beta of 1.04. The company has a current ratio of 1.36, a quick ratio of 1.20 and a debt-to-equity ratio of 0.57. Laboratory Co. of America Holdings has a 1-year low of $174.20 and a 1-year high of $234.09.
Laboratory Co. of America Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.29%. The ex-dividend date of this dividend is Monday, February 26th. Laboratory Co. of America’s dividend payout ratio (DPR) is 38.50%.
Laboratory Co. of America Profile
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development.
- Five stocks we like better than Laboratory Co. of America
- Your Comprehensive Guide to Investing in Bank Stocks
- Uber quadruples EPS estimates, but is growth decelerating?
- Overbought Stocks Explained: Should You Trade Them?
- 3 stocks set to benefit from record Valentine’s Day spending
- How to Use Stock Screeners to Find Stocks
- Tradeweb is a disruptive pure play on financial market liquidity
Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.